Dipeptidyl peptidase-4 (DPP-4) inhibitors

Journal articles and book chapters

10-21-2018 | Sitagliptin | Article

A randomized clinical trial to evaluate the single‐dose pharmacokinetics, pharmacodynamics and safety of sitagliptin in pediatric patients with type 2 diabetes

Fraser IP et al. Pediatr Diabetes 2018. doi: 10.1111/pedi.12790

08-28-2018 | Oral combination medications | Article

Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: A systematic review and meta-analysis

Cai X et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0493-2

08-26-2018 | Oral combination medications | Article

Mechanistic insights from sequential combination therapy with an SGLT2 inhibitor and DPP‐IV inhibitor: Results from the CANARIS trial using canagliflozin and teneligliptin

Okahata S et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13505

08-18-2018 | Medications | Article

Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: A network meta-analysis

Qian D et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0482-5

08-16-2018 | DPP-4 inhibitors | Review | Article

Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: An updated review and challenging clinical scenarios

Gomez-Peralta F et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0488-z

08-09-2018 | Sitagliptin | Article

Adverse drug events associated with sitagliptin versus canagliflozin for the treatment of patients with type 2 diabetes mellitus: A systematic comparison through a meta-analysis

Bundhun PK, Huang F. Diabetes Ther 2018. doi: 10.1007/s13300-018-0481-6

07-30-2018 | Medications | Article

Choice of treatment regimen as add-on to insulin in Japanese patients with type 2 diabetes mellitus: Physicians’ perspective in a real-world setting, insight from a web survey

Imai K, Murayama H, Hirose T. Diabetes Ther 2018. doi: 10.1007/s13300-018-0476-3

07-17-2018 | Heart failure | Article

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Dawwas GK, Smith SM, Park H. Cardiovasc Diabetol 2018; 17: 102. doi: 10.1186/s12933-018-0746-4

06-23-2018 | Sitagliptin | Article

Efficacy and safety of sitagliptin in Hispanic/Latino patients with type 2 diabetes: A pooled analysis from ten randomized, placebo-controlled phase 3 clinical trials

Raji A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0461-x

06-21-2018 | Hypoglycemia | Review | Article

Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

06-15-2018 | Semaglutide | Article

Semaglutide s.c. once-weekly in type 2 diabetes: A population pharmacokinetic analysis

Carlsson Petri KC et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0458-5

06-12-2018 | Empagliflozin | Article

Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

Balijepalli C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0456-7

06-05-2018 | Cardiovascular outcomes | Review | Article

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

06-01-2018 | DPP-4 inhibitors | Article

Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study

Fadini GP et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0452-y

05-30-2018 | Cardiovascular outcomes | Article

Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial

Jarolim P et al. Diabetes Care 2018. doi: 10.2337/dc18-0109

05-28-2018 | Sulfonylureas | Article

Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments

Powell WR, Christiansen CL, Miller DR. Diabetes Ther 2018. doi: 10.1007/s13300-018-0443-z

05-25-2018 | Oral combination medications | Article

Characterization of the open-label lead-in period of two randomized controlled phase 3 trials evaluating dapagliflozin, saxagliptin, and metformin in type 2 diabetes

Mathieu C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0445-x

05-15-2018 | Diet | Article

Glycemic impact of non-nutritive sweeteners: A systematic review and meta-analysis of randomized controlled trials

Nichol AD, Holle MJ, An R. Eur J Clin Nutr 2018. doi: 10.1038/s41430-018-0170-6

05-09-2018 | Liraglutide (T2DM) | Article

Real-world clinical effectiveness and cost savings of liraglutide versus sitagliptin in treating type 2 diabetes for 1 and 2 years

Li Q et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0432-2

05-04-2018 | SGLT2 inhibitors | Review | Article

Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes

Zheng et al. JAMA 2018; 319:1580. doi: 10.1001/jama.2018.3024